康莱特联合经导管肝动脉化疗栓塞术治疗肝癌的效果及对患者血清MMP-9、Bcl-2、VEGF水平的影响  

Effects of kanglaite combined with transcatheter arterial chemoembolization on hepatocellular carcinoma and levels of serum matrix metalloproteinase-9,B cell lymphoma-2 and vascular endothelial growth factor

作　　者：李陆鹏[1] 曹广劭[1] 曹会存[1] 刘建文[1] 刘玉岩[1] 刘瑞青[1] Li Lupeng;Cao Guangshao;Cao Huicun;Liu Jianwen;Liu Yuyan;Liu Ruiqing(Department of General Intervention,Henan Provincial People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]河南省人民医院综合介入科,郑州450000

出　　处：《中国实用医刊》2020年第9期48-52,共5页Chinese Journal of Practical Medicine

摘　　要：目的探讨康莱特联合经导管肝动脉化疗栓塞(TACE)术对肝癌患者肿瘤学疗效及血清基质金属蛋白酶-9(MMP-9)、B细胞淋巴瘤-2(Bcl-2)、血管内皮生长因子(VEGF)水平的影响。方法选取2018年1至2018年9月河南省人民医院收治的100例肝癌患者为研究对象,依据非随机临床同期对照研究及患者自愿原则分为单一组(45例,行TACE术治疗)和联合组(55例,行康莱特联合TACE术治疗)。比较两组肿瘤学疗效,疾病控制率,血清MMP-9、Bcl-2、VEGF水平变化,癌性疼痛[视觉模拟评分法(VAS)],随访复发率及不良反应发生情况。结果治疗后,联合组总有效率(54.55%,30/55)、疾病控制率(83.64%,46/55)高于单一组(31.11%,14/45;66.67%,30/45),P<0.05;与同组治疗前比较,治疗后两组血清MMP-9、Bcl-2、VEGF水平及VAS评分降低,且联合组低于单一组(P<0.05);两组患者均成功获得随访,随访时间6~12(8.58±1.21)个月,联合组治疗后1年随访复发率(10.91%,5/55)低于单一组(24.44%,11/45),χ2=4.341,P<0.05;治疗后联合组Ⅰ/Ⅱ级骨髓抑制、消化道反应、肝功能损害发生率低于单一组(P<0.05)。结论康莱特联合TACE术治疗可有效提高肝癌患者肿瘤学疗效、减轻癌性疼痛并降低复发率,机制或与联合方案能更有效降低血清MMP-9、Bcl-2、VEGF水平有关,且联合治疗方案安全性更好。Objective To investigate the curative effects of kanglaite combined with transcatheter arterial chemoembolization(TACE)on hepatocellular carcinoma(HCC)and their influence on levels of serum matrix metalloproteinase-9(MMP-9),B cell lymphoma-2(Bcl-2)and vascular endothelial growth factor(VEGF).Methods One hundred patients with HCC admitted to Henan Provincial People’s Hospital from January 2018 to September 2018 were selected as the research objects.According to the non-randomized clinical concurrent controlled study and patient’s self-willingness,patients were divided into the single group(treated by TACE,n=45)and combined group(treated with kanglaite combined with TACE,n=55).The curative effect,disease control rate,changes in serum MMP-9,Bcl-2 and VEGF levels,visual analogue pain score(VAS)on cancer pain,follow-up recurrence rate and occurrence of adverse reactions were compared between the two groups.Results After treatment,the total response rate and disease control rate of the combined group(54.55%,30/55;83.64%,46/55)were significantly higher than those of the single group(31.11%,14/45;66.67%,30/45),P<0.05.After treatment,the levels of serum MMP-9,Bcl-2,VEGF and VAS scores in both groups were significantly decreased,and the levels in the combined group were lower than those in the single group(P<0.05).Both groups were successfully followed up,and the follow-up time was 6 to 12(8.58±1.21)months.The recurrence rate of the combined group during 1 year of follow-up after treatment was 10.91%(5/55),significantly lower than the 24.44%(11/45)of the single group(χ2=4.341,P<0.05).After treatment,the incidences of I/II level bone marrow suppression,gastrointestinal reactions and liver damage in the combined group were significantly lower than those in the single group(P<0.05).Conclusions Kanglaite combined with TACE can effectively improve the curative effects on HCC,reduce cancer pain and recurrence rate.The mechanism may be related to the combined treatment decreasing serum MMP-9,Bcl-2 and VEGF levels.Moreover,t

关 键 词：肝癌 康莱特 经导管肝动脉化疗栓塞术 血清基质金属蛋白酶-9 B细胞淋巴瘤-2 血管内皮生长因子 

分 类 号：R735.7[医药卫生—肿瘤]